Drug intelligence / Profile preview

EMB-034

Development stage: Preclinical
Lead developer: Embold Therapeutics

Overview

EMB-034 is an early-stage therapeutic candidate currently in the discovery phase of development by Embold Therapeutics. It is being investigated for the treatment of Parkinson's disease and other rare neurodegenerative disorders. Embold Therapeutics utilizes an AI-optimized platform to develop its pipeline, which focuses on addressing the underlying biological drivers of neurodegeneration. As of early 2024, the specific molecular target, mechanism of action, and modality of EMB-034 remain confidential and have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on EMB-034.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EMB-034.

Explore the full profile